|
Palo Alto, CA, April 19, 2005 — Telik, Inc. (Nasdaq: TELK) reported new preclinical data that support the company’s ongoing TELCYTA™ (TLK286) clinical development program. The data were reported at the 96 th Annual Meeting of the American Association for Cancer Research, in Anaheim, CA.
- TLK286, a Novel Glutathione Analog Prodrug, Induces Resensitization to Carboplatin in Human Ovarian Cancer, OVCAR3, Platinum Resistant Cells: Telik scientists reported that TELCYTA was not cross-resistant with carboplatin in carboplatin resistant ovarian cancer cells and that the combination of TELCYTA and carboplatin showed synergistic inhibition as measured by the Combination Index method in both platinum resistant as well as platinum sensitive ovarian cancer cells. These studies support the ongoing Phase 3 ASSIST-3 registration trial, in which the combination of TELCYTA and carboplatin is being evaluated in platinum refractory or resistant ovarian cancer.
- TLK286, a Novel Glutathione Analog Prodrug, is Synergistic with Carboplatin and Paclitaxel as a Triplet in Human Cancer Cells: This report described the synergistic inhibitory effects of both doublet and triplet combinations of TELCYTA with platinum and taxane drugs as compared to the individual agents in human ovarian and non small cell lung cancer cells. These data provide support for the two ongoing Phase 2 TELCYTA trials in the first line treatment of locally advanced or metastatic non-small cell lung cancer. One trial is evaluating the combination of TELCYTA , carboplatin and paclitaxel. The second trial is evaluating the combination of TELCYTA and cisplatin. Preliminary from the Phase 2 trials will be reported at the annual meeting of the American Society of Clinical Oncology (ASCO) in May.
- TLK286, a Novel Glutathione Analog Prodrug, Induces G2/M Cell Cycle Arrest and Apoptosis In Vitro in Human Lung, Ovarian and Colon Cancer: This report provided details on the TELCYTA-induced effects on cell cycle progression and apoptosis, or programmed cell death, consistent with its novel mechanism of targeted activation.
About TELCYTA
TELCYTA is a small molecule tumor-activated drug candidate. It is activated by GST P1-1, an enzyme present in cancer cells. Upon activation, an intracellular process known as apoptosis, or programmed cell death, occurs. TELCYTA was discovered through the application of Telik’s proprietary drug discovery technology, TRAP.
About Telik
Telik, Inc. of Palo Alto, CA is a biopharmaceutical company working to discover, develop and commercialize small molecule drugs to treat serious diseases. The company’s most advanced drug development candidate is TELCYTA (TLK286), a tumor-activated small molecule product candidate that is in Phase 3 registration trials in advanced ovarian and non-small cell lung cancer. Telik’s product candidates were discovered using its proprietary drug discovery technology, TRAP, which enables the rapid and efficient discovery of small molecule drug candidates. Additional information is available at www.telik.com.
This press release contains “forward-looking” statements. For this purpose, any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements, including any statements regarding the interim results of testing and clinical trials and the potential for TELCYTA (TLK286) to treat one or more types of cancer. There are a number of important factors that could cause Telik's results to differ adversely and materially from those indicated by these forward-looking statements, including, among others, the following: none of Telik’s product candidates, including TELCYTA, has been determined to be safe or effective in humans or received regulatory approval for marketing; it may take us several years to complete clinical trials of our product candidates, including TELCYTA, prior to seeking regulatory approval for any indication; success in preclinical testing and early clinical trials does not ensure that later clinical trials will be successful, and interim results of clinical trials do not necessarily predict final results; if our competitors develop and market products that are more effective than our product candidates, or obtain regulatory approval before we do, our commercial opportunity will be reduced or eliminated; if we do not obtain regulatory approval to market products in the United States and foreign countries, we will not be permitted to commercialize our product candidates; if we are unable to contract with third parties to manufacture our product candidates in sufficient quantities and at an acceptable cost, clinical development of product candidates could be delayed;and if we are unable to raise adequate funds in the future, we will not be able to continue to fund our operations and clinical trials to develop our product candidates. Detailed information regarding factors that may cause actual results to differ materially from the results expressed or implied by statements in this press release may be found in Telik’s periodic filings with the Securities and Exchange Commission, including the factors described in the section entitled “Risk Factors” in our annual report on Form 10-K for the year ended December 31, 2004. TELIK, TRAP, TELCYTA and TELINTRA are trademarks of Telik, Inc. All other brand names or trademarks appearing in this press release are the property of their respective owners. Telik does not undertake any obligation to update forward-looking statements contained in this press release.
###
Contact:
Carol DeGuzman
Senior Director, Corporate Communications
Telik, Inc.
Tel 650-845-7728
Email cdeguzman@telik.com
Go to: 2005 Press Releases2004
Press Releases
2003
Press ReleasesEvents |
